Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether an experimental drug called Hu3F8 can be
given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF.
The investigators want to find out if this combination is safe and what effect it has on the
participant and the disease.